Patents by Inventor Sue Fletcher

Sue Fletcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
    Publication number: 20230063394
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Application
    Filed: August 4, 2022
    Publication date: March 2, 2023
    Applicant: The University of Western Australia
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Abbie ADAMS, Penny MELONI
  • Treatment for NEAT1 associated disease
    Patent number: 11459563
    Abstract: An isolated or purified antisense oligomer for modifying RNA cleavage and processing in the NEAT1 gene transcript or part thereof.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: October 4, 2022
    Assignees: The University of Western Australia, MURDOCH UNIVERSITY
    Inventors: Stephen Donald Wilton, Sue Fletcher, Archa Fox, Ruohan Li
  • Novel Retinitis Pigmentosa Treatment
    Publication number: 20220298506
    Abstract: An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.
    Type: Application
    Filed: May 25, 2020
    Publication date: September 22, 2022
    Inventors: Sue Fletcher, Ianthe Pitout, Jayna Grainok, Steve D. Wilton, Fred K. Chen
  • Antisense molecules and methods for treating pathologies
    Patent number: 11447776
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: September 20, 2022
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Abbie Adams, Penny Meloni
  • ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
    Publication number: 20220170024
    Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for inducing exon inclusion as a treatment for glycogen storage disease type II (GSD-II) (also known as Pompe disease, glycogenosis II, acid maltase deficiency (AMD), acid alpha-glucosidase deficiency, and lysosomal alpha-glucosidase deficiency), and more specifically relates to inducing inclusion of exon 2 and thereby restoring levels of enzymatically active acid alpha-glucosidase (GAA) protein encoded by the GAA gene.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 2, 2022
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Gunnar James HANSON, Richard Keith BESTWICK
  • Antisense-induced exon2 inclusion in acid alpha-glucosidase
    Patent number: 11236338
    Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for inducing exon inclusion as a treatment for glycogen storage disease type II (GSD-II) (also known as Pompe disease, glycogenosis II, acid maltase deficiency (AMD), acid alpha-glucosidase deficiency, and lysosomal alpha-glucosidase deficiency), and more specifically relates to inducing inclusion of exon 2 and thereby restoring levels of enzymatically active acid alpha-glucosidase (GAA) protein encoded by the GAA gene.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: February 1, 2022
    Assignees: SAREPTA THERAPEUTICS, INC., MURDOCH UNIVERSITY
    Inventors: Stephen Donald Wilton, Sue Fletcher, Gunnar James Hanson, Richard Keith Bestwick
  • NOVEL TREATMENT FOR NEAT1 ASSOCIATED DISEASE
    Publication number: 20210355489
    Abstract: An isolated or purified antisense oligomer for modifying RNA cleavage and processing in the NEAT1 gene transcript or part thereof.
    Type: Application
    Filed: February 5, 2018
    Publication date: November 18, 2021
    Inventors: Stephen Donald Wilton, Sue Fletcher, Archa Fox, Ruohan Li
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20210198666
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Application
    Filed: August 19, 2020
    Publication date: July 1, 2021
    Applicant: The University of Western Australia
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 10995337
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: May 4, 2021
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 10968450
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: April 6, 2021
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • ANTISENSE MOLECULES AND METHODS FOR TREATNG PATHOLGIES
    Publication number: 20210040482
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 11, 2021
    Inventors: Stephan Donald WILTON, Sue FLETCHER, Abbie ADAMS, Penny MELONI
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: 10781451
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 22, 2020
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense molecules and methods for treating pathologies
    Patent number: 10781450
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: September 22, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Stephen Donald Wilton, Sue Fletcher, Abbie Adams, Penny Meloni
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20200283772
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: May 22, 2020
    Publication date: September 10, 2020
    Applicant: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Restoration of the CFTR function by splicing modulation
    Patent number: 10731156
    Abstract: Provided are oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, compositions including said oligonucleotides, kits including the compositions, and uses thereof. In particular, the subject matter provides compositions of oligonucleotides useful in methods for suppressing exon skipping optionally in combination with additional CFTR therapeutics.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: August 4, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Batsheva Kerem, Michal Tur Sinai, Loren Price, Stephen Donald Wilton, Sue Fletcher
  • ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
    Publication number: 20200199590
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Application
    Filed: July 31, 2019
    Publication date: June 25, 2020
    Applicant: The University of Western Australia
    Inventors: Stephen Donald WILTON, Sue FLETCHER, Graham MCCLOREY
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: RE47691
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 5, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: RE47751
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 3, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: RE47769
    Abstract: Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 17, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Antisense oligonucleotides for inducing exon skipping and methods of use thereof
    Patent number: RE48960
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 8, 2022
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey